Literature DB >> 22391542

Activity of a novel cyclic lipopeptide, CB-183,315, against resistant Clostridium difficile and other Gram-positive aerobic and anaerobic intestinal pathogens.

D R Snydman1, N V Jacobus, L A McDermott.   

Abstract

We evaluated the activity of CB-183,315 against Clostridium difficile, including strains that are resistant to fluoroquinolones and metronidazole and with elevated MICs to vancomycin as well as other Gram-positive intestinal pathogens. The MICs of CB-183,315 against all C. difficile isolates were ≤ 1 μg/ml. CB-183,315 had greater activity than vancomycin and metronidazole against C. difficile isolates and was more active than the comparators against vancomycin-resistant enterococcus (VRE). CB-183,315 also had excellent activity against methicillin-resistant Staphylococcus aureus (MRSA), other Clostridium spp., and Peptostreptococcus spp.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22391542      PMCID： PMC3370783          DOI： 10.1128/AAC.06257-11

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  13 in total

1.  In vitro activities of CB-183,315, vancomycin, and metronidazole against 556 strains of Clostridium difficile, 445 other intestinal anaerobes, and 56 Enterobacteriaceae species.

Authors:  Diane M Citron; Kerin L Tyrrell; C Vreni Merriam; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2011-12-19       Impact factor: 5.191

2.  Prevalence and clinical features of Clostridium difficile-associated diarrhea in a tertiary hospital in northern Taiwan.

Authors:  Meng Shiuan Hsu; Jann Tay Wang; Wen Kuei Huang; Yung Ching Liu; Shan Chwen Chang
Journal:  J Microbiol Immunol Infect       Date:  2006-06       Impact factor: 4.399

3.  Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin.

Authors:  T Peláez; L Alcalá; R Alonso; M Rodríguez-Créixems; J M García-Lechuz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

4.  Changes in antibiotic susceptibility and ribotypes in Clostridium difficile isolates from southern Scotland, 1979-2004.

Authors:  Surabhi K Taori; Val Hall; Ian R Poxton
Journal:  J Med Microbiol       Date:  2009-11-26       Impact factor: 2.472

5.  Emergence of reduced susceptibility to metronidazole in Clostridium difficile.

Authors:  Simon D Baines; Rachael O'Connor; Jane Freeman; Warren N Fawley; Celine Harmanus; Paola Mastrantonio; Ed J Kuijper; Mark H Wilcox
Journal:  J Antimicrob Chemother       Date:  2008-08-07       Impact factor: 5.790

6.  Clostridium difficile infections in a Canadian tertiary care hospital before and during a regional epidemic associated with the BI/NAP1/027 strain.

Authors:  Annie-Claude Labbé; Louise Poirier; Duncan Maccannell; Thomas Louie; Michel Savoie; Claire Béliveau; Michel Laverdière; Jacques Pépin
Journal:  Antimicrob Agents Chemother       Date:  2008-06-23       Impact factor: 5.191

7.  Typing and susceptibility of bacterial isolates from the fidaxomicin (OPT-80) phase II study for C. difficile infection.

Authors:  D M Citron; F Babakhani; E J C Goldstein; K Nagaro; S Sambol; P Sears; Y-K Shue; D N Gerding
Journal:  Anaerobe       Date:  2009-09-12       Impact factor: 3.331

8.  In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.

Authors:  David W Hecht; Minerva A Galang; Susan P Sambol; James R Osmolski; Stuart Johnson; Dale N Gerding
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

9.  Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile.

Authors:  Jennifer R O'Connor; Minerva A Galang; Susan P Sambol; David W Hecht; Gayatri Vedantam; Dale N Gerding; Stuart Johnson
Journal:  Antimicrob Agents Chemother       Date:  2008-06-16       Impact factor: 5.191

Review 10.  Clostridium difficile PCR ribotype 027: assessing the risks of further worldwide spread.

Authors:  Archie C A Clements; Ricardo J Soares Magalhães; Andrew J Tatem; David L Paterson; Thomas V Riley
Journal:  Lancet Infect Dis       Date:  2010-06       Impact factor: 25.071
View more
  23 in total

Review 1.  Investigational antimicrobial agents of 2013.

Authors:  Michael J Pucci; Karen Bush
Journal:  Clin Microbiol Rev       Date:  2013-10       Impact factor: 26.132

Review 2.  Antibiotics in the clinical pipeline at the end of 2015.

Authors:  Mark S Butler; Mark At Blaskovich; Matthew A Cooper
Journal:  J Antibiot (Tokyo)       Date:  2016-06-29       Impact factor: 2.649

Review 3.  Recurrent Clostridium difficile infection: From colonization to cure.

Authors:  Kelsey Shields; Roger V Araujo-Castillo; Thimmaiah G Theethira; Carolyn D Alonso; Ciaran P Kelly
Journal:  Anaerobe       Date:  2015-04-27       Impact factor: 3.331

4.  In vitro and in vivo characterization of CB-183,315, a novel lipopeptide antibiotic for treatment of Clostridium difficile.

Authors:  Carmela T M Mascio; Lawrence I Mortin; Karen T Howland; Andrew D G Van Praagh; Shuxin Zhang; Anu Arya; Cun Lan Chuong; Chunfeng Kang; Tongchuan Li; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2012-07-16       Impact factor: 5.191

5.  Mutations associated with reduced surotomycin susceptibility in Clostridium difficile and Enterococcus species.

Authors:  Hannah M Adams; Xiang Li; Carmela Mascio; Laurent Chesnel; Kelli L Palmer
Journal:  Antimicrob Agents Chemother       Date:  2015-05-04       Impact factor: 5.191

6.  Impact of Surotomycin on the Gut Microbiota of Healthy Volunteers in a Phase 1 Clinical Trial.

Authors:  Diane M Citron; Kerin L Tyrrell; Suzanne E Dale; Laurent Chesnel; Ellie J C Goldstein
Journal:  Antimicrob Agents Chemother       Date:  2016-03-25       Impact factor: 5.191

7.  Surotomycin demonstrates low in vitro frequency of resistance and rapid bactericidal activity in Clostridium difficile, Enterococcus faecalis, and Enterococcus faecium.

Authors:  Carmela T M Mascio; Laurent Chesnel; Grace Thorne; Jared A Silverman
Journal:  Antimicrob Agents Chemother       Date:  2014-05-05       Impact factor: 5.191

Review 8.  Advances in MRSA drug discovery: where are we and where do we need to be?

Authors:  Michio Kurosu; Shajila Siricilla; Katsuhiko Mitachi
Journal:  Expert Opin Drug Discov       Date:  2013-07-06       Impact factor: 6.098

9.  Effect of Surotomycin, a Novel Cyclic Lipopeptide Antibiotic, on Intestinal Colonization with Vancomycin-Resistant Enterococci and Klebsiella pneumoniae in Mice.

Authors:  Abhishek Deshpande; Kelly Hurless; Jennifer L Cadnum; Laurent Chesnel; Lihong Gao; Luisa Chan; Sirisha Kundrapu; Alexander Polinkovsky; Curtis J Donskey
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

Review 10.  Discovery and development of surotomycin for the treatment of Clostridium difficile.

Authors:  Victoria Knight-Connoni; Carmela Mascio; Laurent Chesnel; Jared Silverman
Journal:  J Ind Microbiol Biotechnol       Date:  2015-12-15       Impact factor: 3.346
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.